REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in two upcoming investor conferences.
Details of the company’s participation are as follows:
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

| Nov-16 | |
| Nov-16 |
RevMed CEO on tackling complex launch for wonder pancreatic drug
RVMD -3.15%
Pharmaceutical Technology
|
| Nov-09 |
Trump's Plan to Lower Drug Prices in U.S. Is Leading to Fewer New Drugs in Europe
RVMD +4.09% RVMD -3.54%
The Wall Street Journal
|
| Nov-05 | |
| Nov-05 | |
| Nov-05 |
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
RVMD -11.04%
Investor's Business Daily
|
| Nov-04 | |
| Nov-04 | |
| Oct-29 | |
| Oct-27 | |
| Oct-27 | |
| Oct-27 | |
| Oct-25 |
ESMO26: Clinical progress shifts a historically difficult pancreatic cancer landscape
RVMD
Clinical Trials Arena
|
| Oct-23 | |
| Oct-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite